NCT03270800View on ClinicalTrials.gov

Phase 1a/b Study on Safety of IMX101 in H. Pylori-negative and H. Pylori-infected Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

January 30, 2017

Primary Completion Date

December 23, 2018

Study Completion Date

December 23, 2018

Conditions
Helicobacter Pylori Infected SubjectsHelicobacter Pylori Naive Subjects
Interventions
BIOLOGICAL

CTA control

Sublingual and intradernal application of a mucosal adjuvance, drug product is not yet on the market.

BIOLOGICAL

IMX101 vaccine

Sublingual and intradermal application of a vaccine, drug product is not yet on the market.

Trial Locations (2)

Unknown

ClinicalTrial Site, Hamburg

Clinical Trial Site, Munich

Sponsors

Lead Sponsor

ImevaX
All Listed Sponsors
lead

ImevaX

INDUSTRY